NATHBIOGEN — Nath Bio-Genes (I) Balance Sheet
0.000.00%
- IN₹3.18bn
- IN₹3.52bn
- IN₹3.65bn
- 47
- 72
- 59
- 66
Annual balance sheet for Nath Bio-Genes (I), fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 292 | 41.7 | 380 | 774 | 885 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,133 | 203 | 1,322 | 1,021 | 987 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,239 | 4,702 | 5,208 | 5,717 | 6,900 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,333 | 2,329 | 2,340 | 2,406 | 2,432 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 7,895 | 7,419 | 7,928 | 8,802 | 10,262 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,730 | 1,967 | 2,165 | 2,624 | 3,653 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,762 | 1,999 | 2,196 | 2,703 | 3,818 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 6,133 | 5,420 | 5,732 | 6,099 | 6,444 |
| Total Liabilities & Shareholders' Equity | 7,895 | 7,419 | 7,928 | 8,802 | 10,262 |
| Total Common Shares Outstanding |